Business
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026
DUBLIN, February 11, 2026--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 25, 2026 to discuss the company’s fourth quarter and year-end 2025 financial results. Management will also discuss financial expectations for 2026 and provide an update on the company.
About this update from Alkermes Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/9d5b3b6172c0b307643e4b6a174f671c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/V6Nrz3ZXbw7b9a1ctaSYTg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/9d5b3b6172c0b307643e4b6a174f671c","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/pg97nV9TTVrFioW5HdkTgA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/9d5b3b6172c0b307643e4b6a174f671c","width":1024,"height":512}},"lazy":false},{"type":"text","content":"DUBLIN, February 11, 2026--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 25, 2026 to discuss the company’s fourth quarter and year-end 2025 financial results. Management will also discuss financial expectations for 2026 and provide an update on the company.","length":360,"tagName":"p"},{"type":"text","content":"The webcast player and accompanying slides may be accessed on the Investors section of Alkermes’ website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes’ website.","length":403,"tagName":"p"},{"type":"text","content":"About Alkermes plcAlkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.","length":728,"tagName"...